Could a new drug combo beat elephantiasis?

NCT ID NCT04410406

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called moxidectin, combined with other medicines, works better than the standard treatment (ivermectin combinations) for lymphatic filariasis, a parasitic disease that can cause severe swelling. 164 adults with the infection received a single dose of one of four drug combinations. Researchers checked blood samples over 36 months to see if the parasites were cleared. The goal is to find a more effective single-dose treatment to help control and eventually eliminate the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Moxidectin (Mox) 8 mg, Ivermectin (IVM) 200 µg/kg, Diethylcarbamazine (DEC) 6 mg/kg, Albendazole (ABZ) 400 mg
What this could lead to
If moxidectin combinations work better, this could offer a more effective single-dose treatment for lymphatic filariasis, reducing transmission and disease burden.
What could go wrong
This is a completed Phase 3 trial with 164 participants, so results are available but may not apply to all populations. The drugs can cause side effects like dizziness or allergic reactions, and long-term benefits are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHATIC FILARIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Regional Hospital of Agboville, Southern Cote d'Ivoire

    Agboville, Côte d’Ivoire

More trials for these conditions

Other studies related to the condition(s) this trial covers.